← Leaderboards
John C Kissel
Ohio State University
$1,216,123
Attributed
$1,216,123
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $257.8K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$1,216,123 · 16
By mechanism
M01$705,517 · 13
P01$478,106 · 1
R13$24,500 · 1
U13$8,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dosage”
- Merit E Cudkowicz · Massachusetts General Hospital$49,193,090
- Karen L. Kotloff · University Of Maryland Baltimore$36,475,194
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- John C S Breitner · Johns Hopkins University$26,933,626
- Lisa C Rohan · Magee-Women'S Hospital Of Upmc$24,562,186
- Daniel M Corcos · Northwestern University$23,636,810
Research focus
DosageClinical ResearchHuman SubjectFundingResearch PersonnelMuscular DystrophyHuman Therapy EvaluationClinical TrialsInstitutionGrantResourcesSourceArsenicDustUnited States National Institutes Of HealthMuscle StrengthComputer Retrieval Of Information On Scientific Projects DatabasePesticidesMuscle Disorder ChemotherapyEnvironmental ToxicologyBiomedical FacilityDrug Screening /EvaluationPlacebosBase
Grant awards (33)
ISES Annual Conferences 2012-2014$8,000
U13 · FY2012 · ES · contact PI
Core--Exposure Assessment$68,483
P01 · FY2008 · ES · contact PI
CLINICAL TRIAL: TRIAL OF VALPROIC ACID AND CARNITINE IN PATIENTS WITH SPINAL MUS$55,090
M01 · FY2008 · RR · contact PI
VALPROIC ACID IN AMBULANT ADULTS WITH SMA$22,521
M01 · FY2008 · RR · contact PI
STUDY OF SR 57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$2,079
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: THYMECTOMY TO NO THYMECTOMY IN NON -THYMOMATOUS MG PATIENTS$346
M01 · FY2008 · RR · contact PI
TRIAL OF VALPROIC ACID AND CARNITINE IN PATIENTS WITH SPINAL MUSCULAR ATROPHY$219,427
M01 · FY2007 · RR · contact PI
Core--Exposure Assessment$35,320
P01 · FY2007 · ES · contact PI
STUDIES ON OUTCOME MEASURES AND THE NATURAL HISTORY OF SPINAL MUSCULAR ATROPHY$3,082
M01 · FY2007 · RR · contact PI
STUDIES ON OUTCOME MEASURES AND THE NATURAL HISTORY OF SPINAL MUSCULAR ATROPHY$55,964
M01 · FY2006 · RR · contact PI
Core--Exposure Assessment$33,179
P01 · FY2006 · ES · contact PI
PILOT OPEN LABEL TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY$8,215
M01 · FY2006 · RR · contact PI
A TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS$4,108
M01 · FY2006 · RR · contact PI
A 6-MONTH OPEN LABEL TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS$513
M01 · FY2006 · RR · contact PI
STUDIES ON OUTCOME MEASURES AND THE NATURAL HISTORY OF SPINAL MUSCULAR ATROPHY$28,012
M01 · FY2005 · RR
PILOT OPEN LABEL TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY$24,511
M01 · FY2005 · RR
Core--Exposure Assessment$18,715
P01 · FY2005 · ES
A 6-MONTH OPEN LABEL TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS$12,838
M01 · FY2005 · RR
A TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS$7,586
M01 · FY2005 · RR
Core--Exposure Assessment$25,802
P01 · FY2004 · ES
A Trial of Mycophenolate Mofetil in Myasthenia Gravis$17,522
M01 · FY2004 · RR
A 6-Month Open Label Trial of Mycophenolate Mofetil in Myasthenia Gravis$1,209
M01 · FY2004 · RR
CORE--EXPOSURE ASSESSMENT$98,869
P01 · FY2002 · ES
Conference-International Society of Exposure Analysis$24,500
R13 · FY2002 · ES
DB TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY$193,916
M01 · FY2001 · RR
CORE--EXPOSURE ASSESSMENT$98,869
P01 · FY2001 · ES
CORE--EXPOSURE ASSESSMENT$98,869
P01 · FY2000 · ES
DB TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY$48,578
M01 · FY2000 · RR
INTRAVENOUS GENTAMICIN IN DUCHENNE MUSCULAR DYSTROPHY$0
M01 · FY2000 · RR
INTRAVENOUS GENTAMICIN IN DUCHENNE MUSCULAR DYSTROPHY$0
M01 · FY2000 · RR
PHASE I CLINICAL TRIAL UTILIZING GENE THERAPY FOR LGMD$0
M01 · FY2000 · RR
PHASE I CLINICAL TRIAL UTILIZING GENE THERAPY FOR LGMD$0
M01 · FY2000 · RR
DB TRIAL OF PROVENTIL IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY$0
M01 · FY2000 · RR